asco gi: new data on fgfr inhibition with frontline bemarituzumab in gastroesophageal tumors
Published 3 years ago • 81 plays • Length 13:47Download video MP4
Download video MP3
Similar videos
-
6:23
division of esophageal and upper gi surgery, university of hong kong
-
8:53
esophagal staging&treatment 3
-
2:39
asco health policy fellowship
-
1:13
achalasia treatment with endoscopic balloon dilation
-
30:17
screening and diagnosis of gastric neoplasia
-
4:59
checkmate 648: 1l io-io in advanced esophageal squamous cell carcinoma
-
1:04:22
immunotherapy management of early and advanced gastric, esophageal, gej, and colorectal cancers
-
6:47
guide for standard f covid-19 ag fia nasal (professional use only)
-
13:47
checkmate 577 - is nivolumab adjuvant the standard of care in esophagus and gej?
-
30:31
gastroesophageal cancer: current positioning of immunotherapy
-
5:26
fight update: 1l bemarituzumab in fgfr2b gastric cancer
-
1:45
esophagal types & risks 1
-
1:07
keymaker-u06 substudy 06a: favezelimab or mk-4380 in esophageal cancer
-
1:28
specialized care for esophageal and gastric cancers | dana-farber cancer institute
-
1:26
updates from asco gi: 2023 west oncology
-
5:32
key data on bladder cancer from asco gu 2017
-
0:27
what to look out for at asco gi 2023
-
1:19
a case study: oligometastatic gastroesophageal adenocarcinoma
-
5:02
the best of gastric and gastroesophageal junction cancer at asco gi 2023
-
23:03
asco gi symposium 2013: esophageal and gastric cancer
-
1:24
what to look forward to at asco gi 2022